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Abstract
Mesenchymal stromal cells (MSCs) are multipotent stem cells well known for repairing tissue, supporting
hematopoiesis, and modulating immune and inflammation response. These outstanding properties make MSCs
as an attractive candidate for cellular therapy in immune-based disorders, especially hematopoietic stem cell
transplantation (HSCT). In this review, we outline the progress of MSCs in preventing and treating engraftment
failure (EF), graft-versus-host disease (GVHD) following HSCT and critically discuss unsolved issues in clinical
applications.
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Background
Mesenchymal stromal cells (MSCs), also called mesen-
chymal stem cells, are multipotent progenitors which
were first described by Caplan and colleagues in 1991.
They were first isolated from bone marrow (BM) and
characterized by the ability to differentiate into adipo-
genic, chondrogenic, and osteogenic lineages [1–3]. Sub-
sequently, a growing body of evidence suggests that
MSCs can also be isolated from various tissue including
umbilical cord blood (UCB), adipose tissue (AT), muscle,
and dental pulp [4, 5]. Nowadays, due to the capacity to
modulate immunological responses, support hematopoiesis,
and repair tissue [6–8], MSCs have been widely used to
treat immune-based disorders, such as Crohn’s disease,
rheumatoid arthritis, diabetes, and multiple sclerosis
[9–12]. Based on the animal experiments and clinical
studies, the most successfully clinical application of
MSCs is involved in hematological disease. In this re-
view, we aim to elaborate the administration of MSCs
in hematopoietic stem cell transplantation (HSCT) and
aplastic anemia (AA), highlight the progress in MSCs
functional features and the mechanisms of MSCs in
clinical treatments.
MSCs phenotype, characteristics, and expansion
MSCs are defined as non-hematopoietic, plastic-adherent,
and self-renewing cells that are capable of differentiating
into adipose, bone, and cartilage in vitro [13]. The Inter-
national Society for Cellular Therapy (ISCT) has listed a
panel of markers for identifying MSCs [13]. The minimum
criteria of MSCs have been commonly used as follows:
(1)Adherence to plastic in vitro culture
(2)Surface antigens positive expression for CD105,
CD73, CD90, and negative for markers including
CD45, CD34, CD14 or CD11b, CD79α or CD19,
and HLA-DR
(3)Differentiation into osteoblasts, adipocytes, and
chondrocytes in vitro
Subsequently, more cell-surface markers were discov-
ered, such as stromal precursor antigen-1 (STRO-1),
stage specific embryonic antigen-4 (SSEA-4), CD49a,
CD271, CD146, and leptin receptor [14–19]. Apart from
the emerging new markers, Edita Hamzic and colleagues
showed that MSCs markers in AA patients differ from
those in healthy people. Moreover, MSCs in AA patients
exhibit significantly reduced hematopoiesis-supporting
capacity [20]. Boome et al. also revealed that some spe-
cific biomarkers of MSCs in graft-versus-host disease
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(GVHD) patients express differently. The different ex-
pressions of these markers are good predictors for dis-
ease occurrence, resolution, and survival [21]. Therefore,
it would be useful to explore more specific markers for
diagnostic and prognostic applications.
In addition to the development of MSCs markers,
exploration of efficient expansion of MSCs also plays an
important role in clinical applications. In the fields of
hematological diseases, MSCs are mainly derived from
BM and UCB. However, MSCs only constitute less than
0.01 % overall cell population resident in BM, which is the
major barrier for clinical usage [22]. An array of studies
found that MSCs also rapidly lose their proliferation
potential and multipotency through rounds of in vitro
culture [23, 24]. Therefore, producing clinical-scale
MSCs and maintaining their high proliferation potential
and multipotency become very important. Recently, to in-
crease the productivity of MSCs, researchers are applying
different strategies by changing the culture media, opti-
mizing culture density, eliminating hematopoietic stem
cells and genetic modification [25–27].
The function of MSCs
In general, MSCs possess the capacity to differentiate
into various types of cells, home to sites of inflamma-
tion, repair tissue, modulate immune or inflammation
response, and support hematopoiesis. Firstly, MSCs have
been identified for their ability to differentiate into the
bone, adipocytes, and cartilage [13]. With an increasing
understanding of MSCs, investigators found that MSCs
are capable of differentiating into all three germ layers
[28–33]. And in some specific microenvironment, for
example, injury, MSCs could differentiate into the lung
epithelial cells in lung injury [34, 35] and into cardio-
myocytes in myocardial infarction (MI) [36, 37]. Sec-
ondly, MSCs also have the ability to migrate to the sites
of inflammation [38–40]. Using biofluorescence imaging
technology, Joo and his colleagues monitored the deliv-
ery and biodistribution of red fluorescent protein (RFP)-
labeled MSCs in GVHD model. They found that MSCs
could first and rapidly home to the lungs, then migrate
to other GVHD-injured organs, including the liver,
esophagus, stomach, small intestine, and large intestine
[41]. Furthermore, Hu et al. showed that CM-Dil-labeled
MSCs can migrate to the thymus in aGVHD murine
model [42]. Some researchers proposed that the degree
of inflammation and different disease status might affect
the distribution of MSCs. However, restricted by detect-
ing method, tracing MSCs in deep target organs is hin-
dered. Recent developed magnetic particle imaging
allows researchers to accurately and quantitatively trace
MSCs distribution [43]. Guided by the chemokines re-
leased from tissue or endothelial cells, MSCs migrate to
specific sites and secrete large quantities of bioactive
molecules to mediate repair [44, 45]. Lastly, MSCs also
co-localize with hematopoietic stem cells (HSCs) in BM
niche and produce factors recruiting HSCs and support-
ing hematopoiesis [46].
The highlight of MSCs function is its immune modula-
tory effects (Fig. 1). The mechanisms that MSCs regulate
immune responses include interacting with various im-
mune cells and secreting soluble mediators in different
microenvironment [44, 45, 47, 48]. Initially, MSCs can ex-
press several adhesion molecules, including vascular cell
adhesion molecule (VCAM)-1, intercellular cell adhesion
molecule (ICAM)-1, and lymphocyte function-associated
antigen (LFA)-3 involved in T-cell interactions, which re-
sult in the discovery of immunomodulatory properties of
MSCs [49]. Further studies demonstrated that MSCs can
not only suppress T-cell proliferation and activation, but
also can regulate the differentiation of helper T (Th) cells
[49, 50]. As an important subpopulation of T helper cells,
regulatory T cells (Tregs) play a crucial part in inducing
peripheral immune tolerance. MSCs can promote the gen-
eration of Tregs to prevent GVHD [51]. Moreover, MSCs
are capable of inhibiting B-cell activation, proliferation,
and the secretion of immunoglobulin (Ig) [52]. Our group
recently documented that interleukin (IL)-10 produced by
MSCs significantly increased CD5+ regulatory B cells
(Bregs) production [53]. MSCs can increase the number
of memory B lymphocytes and enhance B-cell activating
factor receptor (BAFF-R) expression level on B lympho-
cytes [54]. MSCs also modulate immune responses by
inhibiting differentiation of precursors into dendritic cells
(DCs) as well as suppressing DCs maturation [55]. MSCs
may inhibit DCs differentiation by producing IL-6 and
macrophage colony-stimulating factor (M-CSF). And im-
mature DCs generation in the presence of MSCs was sig-
nificantly inhibited because MSCs induced the activation
of T cells [56]. Finally, besides direct cell-to-cell contact
mechanisms, MSCs also indirectly modulate immune re-
sponse by producing many growth factors and cytokines,
including transforming growth factor (TGF)-β, IL-6, pros-
taglandin E2 (PGE2), hepatocyte growth factor (HGF),
indoleamine 2,3-dioxygenase (IDO), etc.
In the past, studies on the immunomodulatory effect of
MSCs primarily focused on peripheral immune compart-
ments. Recently, our group found that MSCs reduced the
incidence and severity of cGVHD in aGVHD patients by
improving thymic function [57]. Based on the role of
MSCs in thymus development [4, 58] and our previous
study, we proposed that MSCs could exert immunomodu-
latory effects through central immune compartments.
Besides, the most valuable discovery in recent years is
the plasticity of MSCs in immune and inflammation
regulation [48]. Traditionally, MSCs were considered as
immunosuppression and anti-inflammation mediators
by secreting high level of IDO, NO, PGE2, and TGF-β
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[48, 59]. However, researches recently found that MSCs
are sensors of inflammation and are able to act as a pro-
inflammatory or anti-inflammatory, immune enhancement,
or immunosuppression phenotype depending on the in-
volved inflammatory milieu [48]. The understanding of
MSCs plasticity provides a new paradigm for MSCs-based
cellular therapy and challenges MSCs clinical applications.
Clinical applications of MSCs in HSCT
Currently, MSCs are widely used in hematological dis-
eases, especially in HSCT, which mainly include promot-
ing HSCs engraftment, treating engraftment failure (EF),
poor graft function (PGF) and AA, and preventing and
ameliorating GVHD.
MSCs and hematopoiesis
Some studies indicated that MSCs play a vital role in
modulating BM microenvironment and supporting
hematopoiesis [46, 60, 61]. The capacity of MSCs to en-
hance engraftment has been proved in animal models
[62, 63]. In clinical practice, MSCs are co-infused with
HSCs to promote hematological engraftment and pre-
vent EF and PGF. The first clinical trial on the use of
MSCs promoting hematopoietic recovery is that autolo-
gous MSCs with HSCs were co-administered in breast
cancer patients after high-dose chemotherapy [64]. Later,
Lazarus et al. demonstrated that, when co-infused with
HSCs, HLA-identical sibling donor derived MSCs were
able to promote hematopoietic recovery in hematologic
malignancy patients after HSCT [65]. In another pediatric
study, MSCs were co-transplanted in 13 pediatric patients
given UCB-derived HSCs. However, there was no sig-
nificant difference between MSC-treated patients and
histological controls in hematological engraftment [66].
Although there are still controversial on the efficacy of
MSCs for hematopoietic engraftment, most published
data demonstrated co-transplanting MSCs and HSCs
were feasible and safe [60, 65, 67].
With regard to those patients developing to EF or
PGF, MSCs could also be considered as a novel ap-
proach for these complications after HSCT. Taking EF
after HSCT as an example, Meuleman et al. adopted
MSCs without co-transplantation of HSCs to treat graft
failure after HSCT [46]. Two of six EF patients achieved
hematopoietic recovery after MSCs infusion, whereas
four patients showed no response upon treatment. Based
on Meuleman’s pilot study, we enrolled 22 patients, ran-
domly assigned them into two groups and performed
two cycles of treatments with MSCs or MSCs plus cord
blood (CB), respectively [68]. After the first treatment
cycle, 7 of 11 patients in MSC group had response, while
9 of 11 in MSC plus CB group (P = 0.635). There was a
significant improvement in neutrophil reconstruction in
MSC plus CB group compared with MSC group (P =
0.030). After the second treatment cycles, the overall re-
sponse (OR) rate increased to 86.36 %. Therefore, our
data indicated that these two strategies are both effective
for EF treatment. Another study conducted in our group
Fig. 1 Immunomodulatory effects of MSC. MSCs exert immunomodulatory effects mainly through central and peripheral immune compartments.
MSCs modulate central immune compartments by repairing damaged thymus, promoting T-cells maturation, inducing the proliferation of natural
Tregs, and differentiating to thymocytes. MSCs modulate peripheral immune compartments, including interacting with various immune cells and
secreting various soluble mediators involved in different microenvironment. They suppress T cell and B cell proliferation, induce the generation
and proliferation of Tregs and Bregs, inhibit differentiation of precursors into DCs, suppress DCs maturation, and influence the function of NK cells
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also showed that 17 out of 20 patients with PGF after
allogeneic HSCT (allo-HSCT) responded to MSCs treat-
ment, accompanied with an increased ratio of CD4+ to
CD8+ T cells after MSCs administration [69].
Given the encouraging results of MSCs in EF and PGF
treatments, the mechanism of MSCs for supporting
hematopoiesis has been explored by several studies. In
HSCT recipients, the hematopoietic microenvironment
is damaged by chemotherapy, irradiation, and malignant
hematological diseases [70, 71]. As a major constituent
of BM microenvironment, MSCs can reconstitute the
damaged stroma and secrete an array of hematopoietic
cytokines, including IL-6, IL-7, IL-8, IL-11, Flt-3 ligand,
and stem cell factor (SCF) to promote self-renew and
differentiation of HSCs [46, 61]. MSCs can also improve
hematopoiesis by modulating the inflammatory micro-
environment and T-cell subtypes, which reduce the
probability of graft rejection [60]. In addition, some
studies found that MSCs promote hematopoietic recov-
ery in AA patients. Our study also observed that six of
18 refractory AA patients (33.3 %) achieved OR after
MSCs treatment, which was significantly higher than
those in historic control cohort (5.56 %) [72]. After
MSCs administration, MSC-treated patients exhibited a
higher Tregs proportion. Thus, MSCs might promote
AA patients hematopoietic recovery by inducing the
generation of Tregs. Nonetheless, Diego V et al. showed
that infusion of MSCs have no effect in refractory or
relapsed AA patients in their clinical trial [73]. Some
studies found that MSCs in AA patients presented dis-
tinctive markers, with decreased proliferative and haemo-
poiesis capacity [20]. Thus, MSCs as a therapeutic strategy
for patients with AA are still controversial. Whether the
characteristics of inherent MSCs in EF and PGF patients
will change need to be further explored.
MSCs and GVHD
GVHD remains the common and life-threatening compli-
cation limiting the widespread use of allo-HSCT, as
GVHD associates with a high mortality and morbidity
[74–77]. To date, new therapeutic agents have been made
in GVHD prophylaxis. The efficacy of MSCs for GVHD
prophylaxis varies in different studies [65, 78, 79]. Lazarus
HM et al. reported that 28 % of patients developed
aGVHD after co-infusion of MSCs with HSCs, while the
incidence of aGVHD in patients who received only HSCs
was 56 % in the historic control group [65]. Another study
in Belgium investigated that MSCs given 30–120 min
before peripheral blood stem cells (PBSCs) infusion sig-
nificantly decreased the incidence of aGVHD [78]. Re-
cently, patients in a prospective clinical trial were
randomly divided into standard GVHD prophylaxis group
and standard GVHD prophylaxis combining with MSCs
group. MSCs were administered when the blood counts
indicated recovery. The data supported that MSCs admin-
istration for aGVHD prophylaxis was effective and safe
[80]. Although co-transplanted MSCs with HSCs to some
extent decreased the incidence of aGVHD, most studies
indicated that no statistical significance was shown in
comparison with the historical control group.
Distinguished from the prevention of GVHD, MSCs
application in the fields of aGVHD treatments achieved
great success. Since Le Blanc et al. first reported that
BM-derived MSCs rescued a pediatric patient experien-
cing grade IV refractory aGVHD [81], a number of stud-
ies have been performed to investigate the effect of
MSCs for aGVHD treatment [57, 81–83]. Although the
results are still controversial, most prospective and
retrospective studies suggest that MSCs are effective to
treat aGVHD. A large multicenter study of BM-derived
MSCs for treating steroid-resistant aGVHD from the
European Group for Blood and Bone Marrow Trans-
plantation Mesenchymal Stem Cell Consortium showed
that 30 of 55 patients had a complete response (CR) and
nine showed partial response (PR), and the OR rate was
70.9 % [82]. Another large-scale, single-arm, prospective
multicenter study enrolled pediatric steroid-refractory
aGVHD patients from seven countries [83]. MSCs were
given at a dose of 2 × 106 cells/kg twice a week for four
consecutive weeks. The response rate of GVHD target
organs was respectively 58.5 % for the gastrointestine,
75.6 % for the skin, and 44.4 % for the liver. OR rate of
refractory aGVHD patients treated with MSCs was 61.3 %.
In our study, we designed a prospective study dividing re-
fractory aGVHD patients to MSC group and non-MSC
group. Combined with pre-existing aGVHD treatment,
MSCs were intravenously infused once a week until
aGVHD got CR or MSCs had been administered for a total
of eight doses. Our results showed that OR rate was 75 %
in MSC group, comparing with 42.1 % in non-MSC group
(P = 0.023). Interestingly, we also found that the incidence
of cGVHD decreased in MSC group compared with non-
MSC group [57]. However, an American clinical trial evalu-
ated the effect of an industrial MSCs product (Prochymal)
and found that industrial MSCs failed to achieve a signifi-
cant increase of CR rate in steroid-resistant GVHD patients
compared with placebo [84]. Another study in Germany
also showed a negative response to MSCs treatment in
steroid-resistant aGVHD patients. MSCs were isolated
from third-party donors and expanded in platelet lysate-
containing medium. The OR rate and overall survival (OS)
were not significantly different from those historical cohorts
without MSCs treatment [85]. The patients in German
study were old people who experienced more severe grade
of aGVHD and extensive organ involvement. Therefore, it
has been taken into consideration that the effects of MSCs
for treating refractory aGVHD vary in different clinical
trials, target organs, and even individuals.
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MSCs for aGVHD treatments have been paid extensive
attention, but the efficacy of MSCs for cGVHD has rarely
been reported. As an autoimmune disorder, cGVHD has
distinct manifestations from those of aGVHD [86]. Ini-
tially, a few studies showed that only limited and transient
benefit could be observed in cGVHD patients after MSCs
administration [87, 88]. Nonetheless, significant improve-
ment has been reported by Weng et al. in refractory
cGVHD patients after MSCs administration [89]. Fourteen
of 19 refractory cGVHD patients receiving BM-derived
MSCs treatment got OR, and the OR rate was 73.6 %.
Consistent with Weng’s report, our group showed that 20
of 23 refractory cGVHD patients had a CR or PR in a
12-month follow-up study [53]. The most obvious im-
provements in cGVHD target organs were the skin, oral
mucosa, and liver. Forcing on some specific cGVHD
organs, Zhou et al. showed that MSCs were adminis-
tered in four patients with sclerodermatous cGVHD
(ScGVHD) by intra-BM injection [90]. Correspond-
ingly, symptoms gradually improved in all four patients.
Moreover, our group recently observed that the treat-
ment of MSCs for bronchiolitis obliterans syndrome
(BOS) was effective, which is the only single patho-
pneumonic manifestation of cGVHD according to the
National Institutes of Health (NIH) [91, 92]. Fifty-three
patients with refractory BOS were enrolled in our pro-
spective study, including 29 patients in MSC group and
24 patients in non-MSC group. The OR rate in MSC
group (75.9 %) was significantly higher than that in
non-MSC group (16.7 %). And the efficacy of MSCs to
refractory BOS was significantly related to the severity
of pulmonary function [92].
Although current studies demonstrate the encouraging
treatment effects of MSCs for cGVHD patients, the re-
sponsiveness of MSCs to aGVHD patients is superior
to that of cGVHD [80]. The differences between the
treatments for aGVHD and cGVHD might relate to the
different mechanisms of MSCs for a/cGVHD treat-
ments. It is well known that T cells play crucial roles in
the development of aGVHD. Joo et al. reported that
MSCs could migrate to the damaged organs in aGVHD
murine model, such as the lungs, gut, liver, skin, thymus,
and lymph nodes [41]. As a sensor in local microenviron-
ment, MSCs can sensitively receive inflammation signals to
exhibit their immune and inflammation regulation effects
by indirectly secreting various cytokines or chemokines and
directly interacting with peripheral immune cells, inducing
the generation and proliferation of Tregs [44, 45, 47, 48].
Moreover, our group found that MSCs can ameliorate
aGVHD through central immune compartments. MSCs
improve thymic output function and reconstruct damaged
thymic structure which induced a long-term immune toler-
ance [57, 58]. And MSCs modulate cGVHD through influ-
encing the function of B lymphocytes. By analyzing the
clinical samples of cGVHD patients, our group demon-
strated that MSCs promote B-lymphocyte reconstruction
and sustain B-lymphocyte homeostasis by increasing naive
and memory B-cell subsets in responsive cGVHD patients,
and modulating plasma BAFF levels and BAFF-R expres-
sion on B lymphocyte [54]. In addition, our further study
also found that MSCs promote regulatory CD5+ B cells
(Bregs) proliferation in responsive cGVHD patients [53].
Nowadays, an increasing number of researchers pay
their attention to the therapeutic differences of MSCs
treatment in GVHD individuals. So, it will be meaningful
to know what kinds of patients may benefit from MSCs
treatment. GVHD biomarker profiling plays an indicative
role on occurrence, resolution, or survival in the context
of GVHD come from the analysis of MSCs treatment.
Boome et al. first performed a prospective study to explore
the relationship between clinical outcomes and the level
of soluble biomarkers. Forty-eight steroid-refractory
aGVHD patients with MSCs treatment were enrolled in
this study. The results showed that the 1-year OS in
MSC-treated patients can be predicted by soluble bio-
markers, including IL-2 receptor α, tumor necrosis factor
(TNF) receptor 1, HGF, regenerating islet-derived protein
3α, and elafin [21]. In another study, tumorigenicity 2
(ST2) has been reported as a strong predictive marker for
non-response to GVHD therapy [93]. Therefore, further
prospective clinical trials are needed to discover more bio-
markers to guide MSCs treatment.
MSCs and infection, relapse
Currently, it is still controversial on whether MSCs in-
crease the incidence of infection and tumor recurrence. In
the past, some studies showed that MSCs increased the
risk of infections and tumor relapse by suppressing T-cell
response and secreting some cytokines, including VEGF
and IL-6 [94–96]. Ning et al. reported that MSCs increased
the risk of tumor relapse in patients co-transplanted HSCs
with MSCs to prevent GVHD [95]. However, our studies
showed that the incidence of infection and tumor relapse
did not increase after MSCs treatment for aGVHD, EF, and
PGF [57, 69], which was consistent with other recent
studies [40, 57, 68, 69, 97–99].
Another interesting discovery is that MSCs possess the
potential to control bacteria, viruses, and protozoal para-
sites infections. Jeffery J et al. proposed that MSCs
exerted their antimicrobial ability by direct effects on
the pathogen or indirect effects through secreting sol-
uble factors and enhancing anti-inflammation function
of immune cells [100]. Our group also showed that hu-
man MSCs pre-stimulated with IFN-γ could inhibit the
growth of Toxoplasma gondii via upregulation of GBP-1
[101]. For antivirus effect, MSCs decrease the replication
of cytomegalovirus (CMV) by secreting cytokine IDO
[102]. MSCs cannot suppress the production of viral-
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specific T cells, but can inhibit the function of alloanti-
gen and mitogen-induced T cells [99]. To test the effi-
cacy of MSCs as a novel antimicrobial therapy, the first
clinical trial was applied in sepsis-induced acute lung in-
jury model [103]. The efficacy of MSCs for infections
following HSCT needs to be further explored.
MSCs source, dosage, and therapeutic schedule
There are an increasing number of clinical trials on
MSCs administration in HSCT. However, the efficacy of
MSCs treatment varied in different clinical trials, dis-
eases, target organs, and even different individuals. An
array of factors might influence the effects of MSCs
treatment, such as source of MSCs, dosage to be infused,
therapeutic schedule, and the route and timing of MSCs
administration. Firstly, it is important to recognize that
MSCs are poorly defined by phenotypical or functional
features. No standard has been established for clinical
grade MSCs manufacture. Nowadays, MSCs products
are derived from different tissue (BM, AT, UCB, or pla-
cental), different donors (autologous, donor derived, or
third-party), different laboratories (industrial or manu-
factured by academic centers), and are cultured and ex-
panded from different media and conditions [4, 5, 84,
104]. Subsequently, the number of MSCs infusion has
ranged from 0.4 × 106 to 10 × 106/kilogram of body
weight [57, 82, 105]. Usually, the widely accepted dosage
of MSCs administration is approximately 1 × 106/kilo-
gram of body weight. The therapeutic schedule has also
been designed as single or repeated doses of MSCs in
different intervals. Recently, a study showed that the
characteristics of individuals, for example, the immune
and inflammation microenvironment in vivo, might in-
fluence the effects of aGVHD patients [21]. Thus, the
timing of MSCs infusion is also very important. In
addition, the route of MSCs administration should be
considered. To date, intravenous injection is still the
main route for the delivery of MSCs for hematologic dis-
orders in human trials and animal models. Another pos-
sibility is to administrate MSCs by intra-arterial infusion,
which was reported by Arima et al. in limited three ster-
oid refractory aGVHD patients. MSCs were infused into
mesenteric arteries for gut GVHD and hepatic artery for
hepatic GVHD via selective angiography. But the study
was stopped due to unsatisfied GVHD response [106].
Zhou et al. gave MSCs directly into the BM by the ante-
rosuperior iliac spine to treat ScGVHD, and all the pa-
tients had significant improvements in their GVHD
symptoms [90]. However, whether intra-BM infusion im-
proves the efficacy of MSCs treatment requires further
study. The optimization of therapeutic procedure for
MSCs clinical application also needs large scale and pro-
spective studies.
Conclusions
Nowadays, the most successfully clinical application of
MSCs is involved in HSCT and AA. The efficacy of
MSCs treatment varies in different studies, but the ma-
jority of studies show that MSCs are promising cellular
therapy. However, there are still some hurdles to over-
come. Firstly, standardized process of MSCs production
has not been established, including the source of MSCs,
culture media, and passage, etc. How to establish an effi-
cient expansion system to satisfy MSCs clinical need,
meanwhile maintain the high proliferation potential and
multipotency needs further study. Secondly, MSCs
therapeutic strategies varied in different clinical studies
for treatments of hematological disorders. And advances
in personalized medicine showed that the efficacy of
MSCs treatment might be related with the individual im-
mune and inflammation microenvironment. The opti-
mized route, dose, frequency, and treatment interval of
MSCs administration require better understanding of
the mechanisms of MSCs treatment. Moreover, MSCs
might promote tumor growth and progression, because
they have the ability to suppress immune response and
secrete some mediators driving angiogenesis in theory
[95]. However, MSCs actually exert bidirectional effects
on tumor regulation. They can inhibit tumors by activat-
ing tumor-suppression signaling pathways in a recent
study [40]. Taken together, future success of MSCs ther-
apy will depend on rational optimization of therapeutic
strategies in conjunction with an adequate understand-
ing of therapeutic mechanisms.
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